SCHEMBL7736232

SCHEMBL7736232

CCCCn1ccc(-c2ccccc2OC)c(N)c1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.49
CNR2 P34972 7/20 0.44
CNR1 P21554 2/20 0.40
ICMT O60725 2/20 0.40
GRM2 Q14416 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
JAK2 O60674 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DPP4 P27487 1/20 0.37
UGCG Q16739 1/20 0.37
DUT P33316 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7734365 0.84 ICMT (0.45) TLR8CNR2CNR1ICMTGRM2
SCHEMBL7737859 0.82 MEN1 (0.45) TLR8CNR2CNR1ICMTGRM2
SCHEMBL8160720 0.82 TNF (0.41) TLR8CNR2CNR1GRM2ALDH1A1
SCHEMBL7734451 0.82 TLR8 (0.48) TLR8CNR2CNR1GRM2ALDH1A1
SCHEMBL7736090 0.76 TLR4 (0.43) TLR8GRM2ALDH1A1
SCHEMBL216346 0.76 CNR2 (0.46) TLR8CNR2CNR1GRM2ALDH1A1
SCHEMBL7726225 0.76 NPC1 (0.40) TLR8GRM2ALDH1A1KDM4EGAA
SCHEMBL7736063 0.71 ALDH1A1 (0.42) CNR2GRM2ALDH1A1KDM4ENPSR1
SCHEMBL8154381 0.70 ALDH1A1 (0.55) TLR8CNR2CNR1GRM2ALDH1A1
SCHEMBL8171070 0.70 ALDH1A1 (0.42) TLR8CNR2CNR1GRM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK TLR8 3948/4885CNR2 2441/4885CNR1 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.